Latest Filings

Issuer Activity

Overview :: ABIOMED, Inc. (OQ:ABMD) [?]
Business Focus: Advanced Medical Equipment & Technology Share on StockTwits
Recent Price for ABMD
USD 26.300 N/A (N/A)
NSQ Delayed 15 minutes
Jul 29 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
N/A 30.770 153.25 N/A 1,061.31
1-Day Low 52-Week Low Yield Avg. Volume  
N/A 18.150 0.0% NSQ  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for ABMD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 6:12am ET July 30th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Jul 28/14 Jul 28/14 Minogue Michael R Direct Ownership Stock Option (Right to Buy) M - Exercise or conversion exempt under rule 16b-3 -25,411  
Jul 28/14 Jul 28/14 Minogue Michael R Direct Ownership Common Stock $.01 par value S - Open market or private sale -25,411 $26.30
Jul 28/14 Jul 28/14 Minogue Michael R Direct Ownership Common Stock $.01 par value M - Exercise or conversion exempt under rule 16b-3 25,411 $13.57
Jul 28/14 Jul 25/14 Minogue Michael R Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -51,147  
Jul 28/14 Jul 25/14 Minogue Michael R Direct Ownership Common Stock $.01 par value S - Open market or private sale -51,147 $26.30
Jul 28/14 Jul 25/14 Minogue Michael R Direct Ownership Common Stock $.01 par value M - Exercise or conversion exempt under rule 16b-3 51,147 $13.57
Jul 28/14 Jul 24/14 Minogue Michael R Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -5,825  
Jul 28/14 Jul 24/14 Minogue Michael R Direct Ownership Common Stock $.01 par value S - Open market or private sale -5,825 $26.30
Jul 28/14 Jul 24/14 Minogue Michael R Direct Ownership Common Stock $.01 par value M - Exercise or conversion exempt under rule 16b-3 5,825 $13.57
Jul 2/14 Jun 30/14 Sutter Martin P Direct Ownership Common Stock, $0.01 par value A - Grant, award or other under Rule 16b-3(d) 646  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for ABMD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 6:12am ET July 30th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Jul 28/14 Jul 28/14 Minogue Michael R Direct Ownership Stock Option (Right to Buy) M - Exercise or conversion exempt under rule 16b-3 -25,411  
Jul 28/14 Jul 25/14 Minogue Michael R Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -51,147  
Jul 28/14 Jul 24/14 Minogue Michael R Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -5,825  
Jul 28/14 Jul 28/14 Minogue Michael R Direct Ownership Common Stock $.01 par value S - Open market or private sale -25,411 $26.30
Jul 28/14 Jul 28/14 Minogue Michael R Direct Ownership Common Stock $.01 par value M - Exercise or conversion exempt under rule 16b-3 25,411 $13.57
Jul 28/14 Jul 25/14 Minogue Michael R Direct Ownership Common Stock $.01 par value S - Open market or private sale -51,147 $26.30
Jul 28/14 Jul 25/14 Minogue Michael R Direct Ownership Common Stock $.01 par value M - Exercise or conversion exempt under rule 16b-3 51,147 $13.57
Jul 28/14 Jul 24/14 Minogue Michael R Direct Ownership Common Stock $.01 par value S - Open market or private sale -5,825 $26.30
Jul 28/14 Jul 24/14 Minogue Michael R Direct Ownership Common Stock $.01 par value M - Exercise or conversion exempt under rule 16b-3 5,825 $13.57
Jul 2/14 Jun 30/14 Sutter Martin P Direct Ownership Common Stock, $0.01 par value A - Grant, award or other under Rule 16b-3(d) 646  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Key People
Michael R. Minogue
Chairman of the Board, President, Chief Executive Officer
Robert L. Bowen
Chief Financial Officer, Vice President, Treasurer
David M. Weber
Chief Operating Officer
William J. Bolt
Senior Vice President - Global Product Operations
Michael G. Howley
Vice President, General Manager - Global Sales and Marketing
Andrew J Greenfield
Vice President - Healthcare Solutions
Company Contact
Address: 22 CHERRY HILL DR
DANVERS MA 01923
Tel: N/A
Website: www.abiomed.com
IR: investors.abiomed.com
Business Overview
ABIOMED, Inc., is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. In April 2014, the Company acquired exclusive license from collaboration partner Opsens Inc. In July 2014, Abiomed Inc acquired ECP Entwicklungsgesellschaft mbH (ECP), medical device company based in Berlin, Germany, and AIS GmbH Aachen Innovative Solutions through ECP.
Financial Overview
For the fiscal year ended 31 March 2014, ABIOMED, Inc. revenues increased 16% to $183.6M. Net income decreased 51% to $7.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Other seeling general increase of 29% to $99M (expense), Other research and development increase of 19% to $28.4M (expense).
Employees: 511 as of Mar 31, 2014
Reporting Currency: U.S. Dollars
Enterprise value: $984.73M as of Mar 31, 2014
Annual revenue (TTM): $183.64M as of Mar 31, 2014
EBITDA (TTM): $10.87M as of Mar 31, 2014
Net annual income (TTM): $7.35M as of Mar 31, 2014
Free cash flow (TTM): $20.71M as of Mar 31, 2014
Net Debt Last Fiscal Year: N/A
Shares outstanding: 40,353,823 as of Jun 27, 2014
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Illumina (OQ:ILMN)
Thermo Fisher Scientific (N:TMO)
Cerner (OQ:CERN)